- Home
- REFI vs VYGR Comparison
REFI vs VYGR Comparison
Compare REFI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- VYGR
- Stock Information
- Founded
- REFI 2021
- VYGR 2013
- Country
- REFI United States
- VYGR United States
- Employees
- REFI N/A
- VYGR N/A
- Industry
- REFI Real Estate Investment Trusts
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- VYGR Health Care
- Exchange
- REFI Nasdaq
- VYGR Nasdaq
- Market Cap
- REFI 255.6M
- VYGR 231.9M
- IPO Year
- REFI 2021
- VYGR 2015
- Fundamental
- Price
- REFI $12.91
- VYGR $4.16
- Analyst Decision
- REFI Strong Buy
- VYGR Strong Buy
- Analyst Count
- REFI 3
- VYGR 7
- Target Price
- REFI $20.00
- VYGR $17.00
- AVG Volume (30 Days)
- REFI 130.6K
- VYGR 661.4K
- Earning Date
- REFI 11-04-2025
- VYGR 11-06-2025
- Dividend Yield
- REFI 15.96%
- VYGR N/A
- EPS Growth
- REFI N/A
- VYGR N/A
- EPS
- REFI 1.69
- VYGR N/A
- Revenue
- REFI $54,287,847.00
- VYGR $42,580,000.00
- Revenue This Year
- REFI $11.43
- VYGR N/A
- Revenue Next Year
- REFI $4.75
- VYGR $107.10
- P/E Ratio
- REFI $7.62
- VYGR N/A
- Revenue Growth
- REFI N/A
- VYGR N/A
- 52 Week Low
- REFI $12.00
- VYGR $2.65
- 52 Week High
- REFI $16.29
- VYGR $7.44
- Technical
- Relative Strength Index (RSI)
- REFI 46.72
- VYGR 39.12
- Support Level
- REFI $12.71
- VYGR $4.40
- Resistance Level
- REFI $13.24
- VYGR $4.71
- Average True Range (ATR)
- REFI 0.23
- VYGR 0.28
- MACD
- REFI 0.03
- VYGR -0.10
- Stochastic Oscillator
- REFI 53.13
- VYGR 0.71
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.